Business Context and Reporting Period
This Form 8-K is a current report filed by Tivic Health Systems, Inc. (not Valion Bio, Inc.) on November 18, 2025. The registrant is a Delaware corporation with principal executive offices in Fremont, California, and its common stock trades on The Nasdaq Stock Market under the symbol TIVC. The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than periodic financial results.
Material Changes and Events
Under Item 8.01 (Other Events), the Company announced it has secured a Techwatch meeting with the Biomedical Advanced Research and Development Authority's (BARDA) Radiological and Nuclear Medical Countermeasures Program staff. The purpose of this meeting is to present:
- Clinical data on Entolimod's effects on radiation-induced injury and acute radiation syndrome.
- Progress on manufacturing readiness.
- Preparations for a biologics license application (BLA).
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding the anticipated outcomes of the BARDA meeting and the development of Entolimod. Management notes that actual results may differ materially from expectations due to known and unknown risks, including those detailed in other SEC filings. No specific financial guidance or numerical outlook is provided in this document.
Investor Verification Checklist
- Verify the exact date and agenda of the scheduled Techwatch meeting with BARDA.
- Review the full text of the press release (Exhibit 99.1) for specific clinical data points presented.
- Confirm the current status of the biologics license application (BLA) preparations.
- Check subsequent filings for the outcome of the BARDA meeting and any resulting regulatory milestones.